GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » EV-to-FCF

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) EV-to-FCF : -74.14 (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bellevue Life Sciences Acquisition's Enterprise Value is $60.65 Mil. Bellevue Life Sciences Acquisition's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.82 Mil. Therefore, Bellevue Life Sciences Acquisition's EV-to-FCF for today is -74.14.

The historical rank and industry rank for Bellevue Life Sciences Acquisition's EV-to-FCF or its related term are showing as below:

BLAC' s EV-to-FCF Range Over the Past 10 Years
Min: -1828.92   Med: 0   Max: 0
Current: -73.86

BLAC's EV-to-FCF is ranked worse than
100% of 156 companies
in the Diversified Financial Services industry
Industry Median: 8.175 vs BLAC: -73.86

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Bellevue Life Sciences Acquisition's stock price is $10.80. Bellevue Life Sciences Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.050. Therefore, Bellevue Life Sciences Acquisition's PE Ratio for today is 216.00.


Bellevue Life Sciences Acquisition EV-to-FCF Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition EV-to-FCF Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - - -72.07

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - -1,752.05 -236.40 -174.66 -72.07

Competitive Comparison of Bellevue Life Sciences Acquisition's EV-to-FCF

For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellevue Life Sciences Acquisition's EV-to-FCF Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Bellevue Life Sciences Acquisition's EV-to-FCF falls into.



Bellevue Life Sciences Acquisition EV-to-FCF Calculation

Bellevue Life Sciences Acquisition's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=60.645/-0.818
=-74.14

Bellevue Life Sciences Acquisition's current Enterprise Value is $60.65 Mil.
Bellevue Life Sciences Acquisition's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bellevue Life Sciences Acquisition  (NAS:BLAC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Bellevue Life Sciences Acquisition's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.80/0.050
=216.00

Bellevue Life Sciences Acquisition's share price for today is $10.80.
Bellevue Life Sciences Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.050.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Bellevue Life Sciences Acquisition EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Website
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004